Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for reduction of liver fat in non-alcoholic fatty liver disease
2009-017080-41Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cannabidiol in metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Liver triglyceride levels after 8 weeks of treatment. Started Mar 2010; status: completed.
02
Drugs
cannabidiol
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2009-017080-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017080-41.